Nivolumab and Low Dose Radiation Therapy in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma

Inclusion Criteria

• Pathologically confirmed Hodgkin lymphoma for whom nivolumab is clinically indicated
• Relapsed/refractory disease
• >= 2 sites of measurable disease, at least one outside of intended RT fields
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Standard laboratory criteria for hematologic, and biochemical, and urinary indices within a range that, in the opinion of the physician, clinically supports enrollment of the subject on the trial
• Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial
• Ability to provide written informed consent

Exclusion Criteria

• Subjects with contraindications to immune checkpoint therapy, as follows:
• Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity
• Prior organ allograft or allogeneic bone marrow transplantation
• Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
• Active autoimmune disease, except for vitiligo, type 1 diabetes mellitus, asthma, atopic dermatitis, or endocrinopathies manageable by hormone replacement; other autoimmune conditions may be allowable at the discretion of the principal investigator
• Condition requiring systemic treatment with either corticosteroids * Systemic steroids at physiologic doses (equivalent to dose of oral prednisone 10 mg) are permitted. Steroids as anti-emetics for chemotherapy are strongly discouraged * Intranasal, inhaled, topical, intra-articular, and ocular corticosteroids with minimal systemic absorption are permitted
• Pregnant women, women planning to become pregnant and women that are nursing